Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

Title
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia
Author(s)
김민경현명수손상균[손상균]오석중[오석중]김병수[김병수]류헌모[류헌모]정주섭[정주섭]주영돈[주영돈]방수미[방수미]정철원[정철원]김동환[김동환]윤성수[윤성수]김인호[김인호]이홍기[이홍기]원종호[원종호]민유홍[민유홍]정준원[정준원]박준성[박준성]엄기성[엄기성]김혁[김혁]박무림[박무림]박진희[박진희]김철수[김철수]김형준[김형준]김여경[김여경]박은경[박은경]장대영[장대영]조덕연[조덕연]문준호[문준호]박선양[박선양]
Keywords
CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSES; CHRONIC-PHASE; RESISTANCE; THERAPY; MESYLATE; CML; PHARMACOKINETICS; OVEREXPRESSION; STI571
Issue Date
201106
Publisher
INFORMA HEALTHCARE
Citation
LEUKEMIA & LYMPHOMA, v.52, no.6, pp.1024 - 1029
Abstract
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 +/- 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with < 1000: 80.6% vs. 19.4%; >= 1000: 94.6% vs. 5.4%; p=0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with < 1000: 3.2% vs. 96.8%; >= 1000: 21.4% vs. 78.6%; p=0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of >= 1000 compared with those with a level of < 1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (< 1000 ng/mL).
URI
http://hdl.handle.net/YU.REPOSITORY/25090http://dx.doi.org/10.3109/10428194.2011.563885
ISSN
1042-8194
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE